Horizon 2020

The TRANBERG®|Thermal Therapy System has not yet a market clearance for Immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA)

Financed with a grant from the EU program for research and innovation, Horizon 2020 (SME Instrument phase 2), CLS carries out a project with the objectives to validate safety and feasability, as well as efficacy and clinical outcome, of imILT® treatment. The project started 1 August, 2016 and runs for 24 months. Within the scope of the project three clinical studies are performed:

 

 

 

 

 

Study A: Pancreatic cancer
Institute Paoli-Calmettes (IPC) i Marseille, France

Study regarding imILT® treatment of advanced pancreatic cancer
Number of patients: 5
Study duration: Ongoing

 
 
Study B: Pancreatic cancer
Portuguese Oncology Institute of Porto, Portugal

Study regarding imILT® treatment of advanced pancreatic cancer
Number of patients: 20
Study duration: Ongoing

horizon_marsielle_481x326